Ering Pharmaceuticals: Lianhua Qing plague has been approved for the registration of drugs in Uzbekistan

Pharma Network January 15 - Ealing Pharmaceuticals on January 14 issued a notice, received by the Ministry of Health of Uzbekistan approved the issuance of drug registration approval documents, approved the company's patented Chinese medicine Lianhua Qing plague capsules in line with Uzbekistan's drug standards registration.
introduction, Lianhua Qing plague is the leading product of Ling Pharmaceuticals, the national basic drug catalog and the national health insurance catalogue (Class A) varieties, mainly used for colds, influenza and new coronary pneumonia-related diseases treatment.
April 2020, China's State Drug Administration approved Lianhua Qing plague capsules/particles to add a new adaptation of "new coronavirus pneumonia light and common" on the basis of the original approved adaptation.
it is understood that before the registration approval, Lianhua Qing plague capsule has been selected in Uzbekistan's anti-epidemic drugs white list.
In accordance with the Measures on Regulating the Circulation of Drugs, Medical Devices and Medical Devices during the New Coronavirus Pandemic issued by the Ministry of Health of Uzbekistan on 11 August 2020, drugs on the whitelist are allowed to enter Uzbekistan without registration for the treatment of patients with neo-coronary pneumonia.
Previously, zhong Nanshan and other academicians jointly participated in 23 hospitals for the treatment of neo-coronary pneumonia, published in May 2020 in the European authoritative journal Phytomedicine, "Chinese medicine Lianhua Qing plague capsule treatment of new coronavirus pneumonia forward-looking, randomized, controlled, multi-center clinical research" The results showed that after 14 days of treatment in the treatment group, the cure rate of the main clinical symptoms (fever, fatigue, cough) was significantly higher than that of the control group, reaching 57.7% on the 7th day of treatment, 80.3% on the 10th day of treatment, and 91.5% on the 14th day of treatment.
studies show that the combined application of Lianhua Qing plague capsules for 14 days on the basis of conventional treatment can significantly improve the rate of improvement of clinical symptoms such as fever, fatigue and cough, significantly improve lung imaging lesions, shorten the duration of symptoms, improve clinical cure rate, and curb the deterioration of neocyclind.
, Lianhua Qing plague capsules have been approved for listing in 21 countries and regions, including Canada, Russia, Romania, the Philippines and Singapore.
Xuefei, general manager of the International Trade Center of Esling Pharmaceuticals, said that in addition to Lianhua Qing plague, Erling Pharmaceuticals is also actively promoting the registration of the company's patented Chinese medicine Lianhua Qing cough tablets overseas.
Lianhua Qing cough is a special drug for patients with trachea-bronchitis cough after Lianhua Qing cough, guided by the theory of traditional Chinese medicine and clinical practice, and another respiratory system patented innovation developed by traditional classics and clinical practice.
the drug was approved in May 2020 by the Hebei Provincial Drug Administration for emergency filing of new crown pneumonia, recommended by the Hebei Provincial Administration of Traditional Chinese Medicine for medical treatment of new crown pneumonia.
According to the introduction, Lianhua Qing cough group to the east Han Zhang Zhongjing "typhoid theory" apricot stone gan soup to vent the lung fever, Ming Dynasty Ye Wenling "medical general purpose" qing jinli sputum soup to clear half summer, before HuQing venting lung fever, sputum cough, mountain silver flowers, even brooding, oxen clear heat detoxification, permeable heat up to the table, large yellow tongs excretion lung.
The clinical efficacy observation of lianhuaqing cough treatment of light, common new coronavirus pneumonia" jointly carried out by hebei Chest Hospital and other 7 hospitals shows that the addition of lianhuaqing cough on the basis of conventional treatment can significantly improve cough, cough sputum symptoms in patients with neo-coronary pneumonia, shorten the duration of cough and sputum symptoms, reduce lung lesions, improve respiratory function, and show good improvement in fever, fatigue, dry throat and sore throat.